Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis

Abstract Background Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD. M...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Panupong Hansrivijit, Wisit Cheungpasitporn, Charat Thongprayoon, Nasrollah Ghahramani
Формат: Artigo
Язык:Inglês
Опубликовано: BMC 2020-04-01
Серии:BMC Nephrology
Предметы:
Rituximab
FSGS
Focal segmental glomerulosclerosis
MCD
Minimal change disease
Nephrotic syndrome
Online-ссылка:http://link.springer.com/article/10.1186/s12882-020-01797-7
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы